中国医药健康产业股份有限公司关于子公司获得药品注册证书的公告

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Tianfang Pharmaceutical, has received a drug registration certificate for Clopidogrel Hydrogen Sulfate Tablets, which is expected to enhance the company's cardiovascular medication product line and provide valuable experience for future generic drug development [1][6]. Group 1: Drug Registration Information - The drug name is Clopidogrel Hydrogen Sulfate Tablets, with a specification of 75mg [1]. - The registration application was accepted by the National Medical Products Administration (NMPA) in January 2024 [3]. - The total investment in the drug development has reached approximately 19.54 million RMB (about 2.95 million USD) [4]. Group 2: Market Situation - As of the announcement date, 21 other companies, including Shijiazhuang Yiling Pharmaceutical, Shenzhen Mindray Bio-Medical Electronics, and Zhejiang Jingxin Pharmaceutical, have also obtained production licenses for this drug [5]. - Clopidogrel Hydrogen Sulfate Tablets are classified as a Category B drug under the medical insurance system, with total domestic sales of approximately 4.924 billion RMB (about 0.74 billion USD) in 2023 and projected sales of about 5.376 billion RMB (about 0.81 billion USD) in 2024 [5].